We communicate about QuitAssist® through our corporate and product websites, email, and direct mail. To build upon the success of QuitAssist® in the future, we must consider the balance between supporting total tobacco cessation for adult tobacco consumers, versus conversion to products that may be less risky than cigarettes, according to individual personal health objectives.
Our recent investments to make progress in cessation have focused on youth. With the rise in e-vapor use among youth, scientific and public health communities have raised legitimate concerns about the effects of nicotine addiction on the developing adolescent brain. In 2018, Altria made significant investments to support prevention and cessation programming to help address youth vaping. For example, we invested in Caron Treatment Centers to develop digital learning tools to scale the reach of their nicotine prevention and cessation programming for youth and education resources for professionals and families.
In addition, Philip Morris USA supported the Duke Center for Smoking Cessation for ten years. They contributed $37 million to this program that funded work through May 2014. Over the years, researchers at the Center have investigated and reported on new and better smoking cessation methods. For example, these researchers developed and validated a new nicotine patch dosing regimen that doubles abstinence rates.